Link Between Lipoprotein(a) Levels and Sarcopenia in Type 2 Diabetes Patients

Link Between Lipoprotein(a) Levels and Sarcopenia in Type 2 Diabetes Patients

November 27, 2024 Catherine Williams - Chief Editor Health

Study Overview

This study examined the link between lipoprotein(a) (Lp(a)) levels and sarcopenia in patients with type 2 diabetes mellitus (T2DM). It aimed to determine if this association varies by sex.

Patient Demographics

A total of 426 T2DM patients were included in the study, with a mean age of 58.6 years. Of these, 56.3% were males. The study was conducted between December 2021 and December 2022. Sarcopenia was diagnosed based on the Asian Working Group for Sarcopenia criteria from 2019.

Key Findings

  • The prevalence of sarcopenia was 31.7%, higher in males (34.2%) than females (28.5%).
  • Among patients, 19.0% had Lp(a) levels ≥ 30 mg/dL.
  • Higher Lp(a) levels correlated with a greater risk of sarcopenia.

Statistical Analysis

  1. Logistic Regression:

    • A significant positive correlation was found between elevated Lp(a) and sarcopenia, with an odds ratio of 2.19 after adjusting for various factors.

  2. Spline Analysis:

    • A linear relationship was evident, indicating that as Lp(a) levels increase, so does the incidence of sarcopenia.
  3. Subgroup Analysis:
    • The risk of sarcopenia associated with Lp(a) was consistent across different age groups and sexes.

Conclusions

The study concluded that elevated Lp(a) (≥30 mg/dL) is linked to an increased risk of sarcopenia in T2DM patients, regardless of sex. Therefore, screening for sarcopenia should be a priority for T2DM patients with high Lp(a) levels.

Implications

These findings suggest that regular monitoring of Lp(a) may be beneficial in managing complications associated with T2DM, particularly sarcopenia. Additional research is necessary to explore whether reducing Lp(a) levels can mitigate risks.

Limitations

The study had limitations, including:

  • Its cross-sectional design, which prevents establishing causation.
  • The patient population was sourced from a single hospital, affecting the generalizability of results.
  • Missing data on factors like nutrition and physical activity may limit insights into sarcopenia.

Future Directions

Future investigations should include larger cohorts and focus on the effects of Lp(a)-lowering treatments on sarcopenia in T2DM.